[Effect of adrenergic and histaminergic disorders on the subclinical course of atopic bronchial asthma].
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism*; D004155:Diphenhydramine / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006634:Histamine H1 Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010545:Peroxides / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D018927:Anti-Asthmatic Agents; D006634:Histamine H1 Antagonists; D010545:Peroxides; D004155:Diphenhydramine; D011433:Propranolol
Vyiavlenie narusheniĭ v adrenergicheskoĭ i gistaminergicheskoĭ sistemakh na doklinicheskom étape pri atopicheskoĭ bronkhial'noĭ astme.